Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2025

Nousias Orestis, Mandell Jeffrey D, Anderson Karen S, Townsend Jeffrey P

Abstract excerpt

Genomic instability driven by stress-response-dependent mutagenesis is a key factor in cancer progression. Tyrosine kinase inhibitor therapy, a common treatment for non-small cell lung cancer, induces mutations that can facilitate the evolution of drug resistance and therapeutic failure. Here we quantified the contribution of APOBEC to mutational signatures in non-small cell lung cancer patients undergoing TKI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Biology Techniques and Applications

Source

Identifiers

PMID: 40090261
DOI: 10.1016/j.lungcan.2025.108487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.PMID 40090261Read ↗

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistanceSemantic proximity Read ↗

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancerSemantic proximity Read ↗

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.Semantic proximity Read ↗

Single-Cell RNA Sequencing in Unraveling Acquired Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: New PerspectivesSemantic proximity Read ↗

Probability Distribution for Rare Neutral Mutations in Cancers and Application to Dynamic Precision Medicine of CancerSemantic proximity Read ↗

APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancerSemantic proximity Read ↗

APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.Semantic proximity Read ↗

Therapy-induced APOBEC3A drives evolution of persistent cancer cells.Semantic proximity Read ↗

Clinically relevant shifts in endogenous and exogenous mutational processes proximate to metastasis support local consolidative treatment in EGFR-driven non-small cell lung cancerSemantic proximity Read ↗

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinomaSemantic proximity Read ↗

Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.Semantic proximity Read ↗

Mathematical Model of Intrinsic Drug Resistance in Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.